LRCX — Lam Research Corporation

The tape is bearish as of 2026-10-16: a record 10-session losing streak, a -16.3% one-week return, RSI 31.0, and price 15.1%/13.7%/5.4% below the 20-, 50- and 200-day SMAs. But the trigger was macro/sector multiple compression in high-beta semis (LRCX beta 1.854), not a company-specific miss - Q4 FY2026 revenue of $6.72B beat and EPS of $1.81 beat consensus of ~$1.69. So positioning and momentum are bearish while fundamentals and the sell-side (39 Buy / 10 Hold / 1 Sell, $375.68 average target) remain bullish. That is a divergence, not a broken story.

Clearly accelerating, not decelerating. Revenue rose in 12 straight quarters from $3.48B (Sep-2023) to $6.72B (Jun-2026), with sequential growth re-accelerating from +0.4% (Dec-2025) to +9.3% (Mar-2026) to +15.1% (Jun-2026) and YoY growth rebounding from +22.2% to +30.0%. Gross margin expanded from ~47.5% to 51.8% and operating margin from ~29-30% to 37.4% over the same span, while diluted EPS nearly tripled from $0.67 to $1.81. The one crack is cash conversion: Q4 FY2026 operating cash flow of $1.457B was down 43% YoY against a 30% revenue increase, and free cash flow fell from $2.382B to $1.268B YoY - a working-capital build (accruals ratio +3.49%) that is normal during a ramp but is the single line worth monitoring.

A split verdict that depends entirely on which earnings base you use. On trailing numbers it is expensive: 46.2x TTM P/E and 14.4x P/S against 5-year averages of 32.6x and 9.4x, with price/book at 26.9x. On forward numbers it is not: at the 2026-10-16 price of $267.45 versus consensus next-FY EPS of $9.527, the forward P/E is 28.1x - below the 5-year average trailing multiple - and the forward PEG is roughly 0.4 against ~65% expected EPS growth (TTM PEG is 1.20). The catch is that the $9.527 EPS and $35.0B revenue estimates may themselves sit near a cyclical peak, which is precisely what the market is discounting.

The stock is priced as if the upcycle stalls. At 28x forward earnings on ~65% expected EPS growth, the market is pairing a below-average multiple with above-average growth - a classic late-cycle set-up with two outcomes: either estimates prove durable and the multiple re-rates toward the 32-33x 5-year norm (roughly 20% upside), or FY2027 is the cyclical peak and today's 28x is really 40x+ on normalized mid-cycle earnings. The beat itself no longer moves the stock - LRCX has now beaten and the tape has stopped paying. The informative datapoint is management's forward WFE and gross-margin commentary, not the headline print.

As of 2026-10-16 the setup was oversold but not obviously capitulated: RSI(14) at 31.0, price 15.11% below the 20-day SMA, 13.68% below the 50-day, and 5.35% below the 200-day. The 200-day gap is small relative to the short-term gaps, meaning the long-term trend is dented rather than broken while the short-term trend is severely stretched after 10 consecutive down sessions. The six-month return is -0.27% versus -14.82% over three months, so the damage is compressed into recent weeks rather than a year-long bleed. Practically, selling the breakdown is late and buying the first bounce is early - with RSI in the low 30s and earnings on 2026-10-21, this likely resolves in a gap, so sizing matters more than timing.

• AI/HBM/advanced-packaging capex: calendar-2026 wafer fab equipment spending forecasts are being revised toward the high-$150B range, the primary demand driver for Lam's deposition, etch and clean tools.
• Semiconductor sector de-rating: broad multiple compression across high-beta hardware names (LRCX beta 1.854) is shrinking the valuation even as earnings estimates rise.
• China export controls and regional demand allocation: regulatory shifts around China shipments remain a recurring source of order and mix volatility.
• Memory cycle exposure: Lam has heavy DRAM/NAND customer concentration, so memory-makers' capex discipline is a larger swing factor than logic/foundry spending.
• Rate and duration sensitivity: at a 46x trailing P/E, the stock stays levered to discount-rate moves and rotation out of long-duration growth equities.

• Q1 FY2027 earnings on 2026-10-21 - the decisive near-term event, with guidance on FY2027 WFE spending, gross-margin trajectory and China mix.
• Further upward revisions to calendar-2026/2027 WFE spending forecasts toward the high-$150B range, which would validate the $35.0B next-FY revenue consensus.
• Annual Meeting of Stockholders on 2026-11-03, including any capital-return (buyback/dividend) updates.
• HBM and advanced-packaging capacity announcements from memory and foundry customers, which pull incremental deposition and etch tool demand forward.

• Cyclical peak risk: next-FY consensus ($35.0B revenue, $9.527 EPS) may be near a cycle top; a memory or logic digestion phase would hit estimates and the multiple at the same time.
• Cash-conversion deterioration: Q4 FY2026 operating cash flow fell 43% YoY to $1.457B while net income rose 32%, an accruals ratio of +3.49% driven by a working-capital build that needs to reverse.
• Valuation reset risk: 46.2x TTM P/E and 14.4x P/S versus 5-year averages of 32.6x and 9.4x leave little cushion for a growth disappointment.
• China export-control exposure and revenue concentration among a small set of memory and foundry buyers.
• High beta (1.854) means sector-wide risk-off episodes hit LRCX harder than the market, as the last month demonstrated.

This looks like a fundamentally strong business in a momentum-driven drawdown rather than a broken one: revenue is accelerating sequentially and YoY, gross margin is at 51.8%, operating margin at 37.4%, ROIC at 40.8%, and the balance sheet carries net cash with a 2.63 current ratio. At 28.1x forward EPS against ~65% expected growth, the risk/reward is materially better than at the June 2026 peak, but this is a cyclical and next-FY consensus may be peak-cycle, so the 2026-10-21 guidance is the gate. A modestly attractive entry for a patient investor, not a clean all-clear.

Applied a 32x forward P/E - roughly in line with LRCX's 5-year average trailing P/E of 32.6x, justified by 50.5% gross margins, 40.8% ROIC and net cash, and well below the ~45x forward multiple the stock carried at its June 30, 2026 peak - to the consensus next-FY EPS estimate of $9.527, yielding $305. I deliberately did not apply the sell-side's implied ~39x, because the next-FY estimates sit near a plausible cyclical peak and a normal up-cycle multiple is the honest anchor.